<DOC>
	<DOC>NCT01513928</DOC>
	<brief_summary>This study is designed to compare the pharmacokinetics of three different formulations of Pf-04937319</brief_summary>
	<brief_title>A Study To Compare The Pharmacokinetics Of Different Formulations Of PF-04937319 In Healthy Subjects</brief_title>
	<detailed_description />
	<criteria>Healthy male and/or female subjects between the ages of 21 and 55 years, inclusive. Healthy is defined as no clinically relevant abnormalities identified by a detailed medical history, full physical examination, including blood pressure and pulse rate measurement, 12lead ECG or clinical laboratory tests. Subjects of childbearing potential must agree to use a highly effective method of contraception throughout the study and for at least 28days after the last dose of treatment. Body Mass Index (BMI) of 23 to 33 kg/m2 and a total body weight &gt;=50 kg (110 lbs). Evidence or history of clinically significant hematological, renal, endocrine, pulmonary, gastrointestinal, cardiovascular, hepatic, psychiatric, neurologic, or allergic disease (excluding untreated seasonal allergies). Any condition possibly affecting drug absorption (eg, gastrectomy). A positive urine drug screen.</criteria>
	<gender>All</gender>
	<minimum_age>21 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>March 2012</verification_date>
	<keyword>pharmacokinetics</keyword>
	<keyword>relative bioavailability</keyword>
	<keyword>formulation comparison</keyword>
</DOC>